{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:57:04Z","timestamp":1787504224998,"version":"build-2736575974"},"reference-count":106,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["No. 81972344"],"award-info":[{"award-number":["No. 81972344"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010270","name":"Capital Health Research and Development of Special","doi-asserted-by":"publisher","award":["No. 7202020"],"award-info":[{"award-number":["No. 7202020"]}],"id":[{"id":"10.13039\/501100010270","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Chimeric antigen receptor T cells (CAR-T) therapy is a prospective therapeutic strategy for blood cancers tumor, especially leukemia, but it is not effective for solid tumors. Glioblastoma (GBM) is a highly immunosuppressive and deadly malignant tumor with poor responses to immunotherapies. Although CAR-T therapeutic strategies were used for glioma in preclinical trials, the current proliferation activity of CAR-T is not sufficient, and malignant glioma usually recruit immunosuppressive cells to form a tumor microenvironment that hinders CAR-T infiltration, depletes CAR-T, and impairs their efficacy. Moreover, specific environments such as hypoxia and nutritional deficiency can hinder the killing effect of CAR-T, limiting their therapeutic effect. The normal brain lack lymphocytes, but CAR-T usually can recognize specific antigens and regulate the tumor immune microenvironment to increase and decrease pro- and anti-inflammatory factors, respectively. This increases the number of T cells and ultimately enhances anti-tumor effects. CAR-T therapy has become an indispensable modality for glioma due to the specific tumor-associated antigens (TAAs). This review describes the characteristics of CAR-T specific antigen recognition and changing tumor immune microenvironment, as well as ongoing research into CAR-T therapy targeting TAAs in GBM and their potential clinical application.<\/jats:p>","DOI":"10.3389\/fphar.2021.661606","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T09:02:17Z","timestamp":1625734937000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Targeting Tumor-Associated Antigen: A Promising CAR-T Therapeutic Strategy for Glioblastoma Treatment"],"prefix":"10.3389","volume":"12","author":[{"given":"Guidong","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fusheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41467-020-20599-x","article-title":"Intratumoral IL-12 Delivery Empowers CAR-T Cell Immunotherapy in a Pre-clinical Model of Glioblastoma","volume":"12","author":"Agliardi","year":"2021","journal-title":"Nat. Commun."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-Specific Chimeric Antigen Receptor-Modified Virus-specific T Cells for Progressive Glioblastoma","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/neuonc\/nos217","article-title":"Prevalence, Clinico-Pathological Value, and Co-occurrence of PDGFRA Abnormalities in Diffuse Gliomas","volume":"14","author":"Alentorn","year":"2012","journal-title":"Neuro-Oncology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"candisc.1661.2020","DOI":"10.1158\/2159-8290.CD-20-1661","article-title":"IFNg Is Critical for CAR T Cell Mediated Myeloid Activation and Induction of Endogenous Immunity","volume":"11","author":"Alizadeh","year":"2021","journal-title":"Cancer Discov."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma: Signaling Pathways and Targeted Therapies","volume":"37","author":"An","year":"2018","journal-title":"Oncogene"},{"key":"B6","doi-asserted-by":"publisher","first-page":"7360","DOI":"10.1158\/1078-0432.CCR-17-1549","article-title":"CD90 Expression Controls Migration and Predicts Dasatinib Response in Glioblastoma","volume":"23","author":"Avril","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"15223","DOI":"10.1038\/ncomms15223","article-title":"PTEN Regulates Glioblastoma Oncogenesis through Chromatin-Associated Complexes of DAXX and Histone H3.3","volume":"8","author":"Benitez","year":"2017","journal-title":"Nat. Commun."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1093\/neuonc\/nou307","article-title":"Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Glioblastoma","volume":"17","author":"Berghoff","year":"2015","journal-title":"Neuro Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/s41388-017-0024-z","article-title":"Immunotherapies for Malignant Glioma","volume":"37","author":"Boussiotis","year":"2018","journal-title":"Oncogene"},{"key":"B10","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The Somatic Genomic Landscape of Glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","article-title":"Optimization of IL13R\u03b12-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma","volume":"26","author":"Brown","year":"2018","journal-title":"Mol. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and Safety of IL13R\u03b12-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e77769","DOI":"10.1371\/journal.pone.0077769","article-title":"Glioma IL13R\u03b12 Is Associated with Mesenchymal Signature Gene Expression and Poor Patient Prognosis","volume":"8","author":"Brown","year":"2013","journal-title":"PLoS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"7218","DOI":"10.1158\/1078-0432.CCR-19-0375","article-title":"NKG2D Controls Natural Reactivity of V\u03b39V\u03b42 T Lymphocytes against Mesenchymal Glioblastoma Cells","volume":"25","author":"Chauvin","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.3389\/fimmu.2018.01004","article-title":"Immune Microenvironment in Glioblastoma Subtypes","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s13046-019-1269-x","article-title":"MET in Glioma: Signaling Pathways and Targeted Therapies","volume":"38","author":"Cheng","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12943-020-01189-3","article-title":"Exosomal Noncoding RNAs in Glioma: Biological Functions and Potential Clinical Applications","volume":"19","author":"Cheng","year":"2020","journal-title":"Mol. Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1038\/emm.2017.9","article-title":"High Prevalence of TP53 Mutations Is Associated with Poor Survival and an EMT Signature in Gliosarcoma Patients","volume":"49","author":"Cho","year":"2017","journal-title":"Exp. Mol. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T Cells Secreting BiTEs Circumvent Antigen Escape without Detectable Toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/cancers9070087","article-title":"Role and Therapeutic Targeting of the HGF\/MET Pathway in Glioblastoma","volume":"9","author":"Cruickshanks","year":"2017","journal-title":"Cancers"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.1158\/0008-5472.CAN-11-3490","article-title":"The MET Oncogene Is a Functional Marker of a Glioblastoma Stem Cell Subtype","volume":"72","author":"De Bacco","year":"2012","journal-title":"Cancer Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.cytogfr.2010.02.007","article-title":"Double Trouble for Tumours: Exploiting the Tumour Microenvironment to Enhance Anticancer Effect of Oncolytic Viruses","volume":"21","author":"De Silva","year":"2010","journal-title":"Cytokine Growth Factor. Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1093\/neuonc\/nox191","article-title":"EGFR Heterogeneity and Implications for Therapeutic Intervention in Glioblastoma","volume":"20","author":"Eskilsson","year":"2018","journal-title":"Neuro Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1093\/neuonc\/now113","article-title":"EGFRvIII Mutations Can Emerge as Late and Heterogenous Events in Glioblastoma Development and Promote Angiogenesis through Src Activation","volume":"18","author":"Eskilsson","year":"2016","journal-title":"Neuonc"},{"key":"B26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.virusres.2013.12.021","article-title":"Antitumor Activities of an Oncolytic Adenovirus Equipped with a Double siRNA Targeting Ki67 and hTERT in Renal Cancer Cells","volume":"181","author":"Fang","year":"2014","journal-title":"Virus. Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00418-018-1633-5","article-title":"NKG2D Ligands in Glioma Stem-like Cells: Expression In Situ and In Vitro","volume":"149","author":"Fl\u00fch","year":"2018","journal-title":"Histochem. Cel Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e32614","DOI":"10.1371\/journal.pone.0032614","article-title":"Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients","volume":"7","author":"Fong","year":"2012","journal-title":"PloS one"},{"key":"B29","doi-asserted-by":"publisher","first-page":"7596","DOI":"10.1158\/0008-5472.CAN-04-1627","article-title":"RNA Interference Targeting Transforming Growth Factor-\u03b2 Enhances NKG2D-Mediated Antiglioma Immune Response, Inhibits Glioma Cell Migration and Invasiveness, and Abrogates Tumorigenicity In Vivo","volume":"64","author":"Friese","year":"2004","journal-title":"Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nrc3918","article-title":"Heterogeneity of Epidermal Growth Factor Receptor Signalling Networks in Glioblastoma","volume":"15","author":"Furnari","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/neuonc\/nou346","article-title":"Microglia in the Tumor Microenvironment: Taking Their TOLL on Glioma Biology","volume":"17","author":"Gutmann","year":"2015","journal-title":"Neuro-Oncology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41418-018-0126-3","article-title":"TP53 Gain-Of-Function Mutation Promotes Inflammation in Glioblastoma","volume":"26","author":"Ham","year":"2019","journal-title":"Cell Death Differ"},{"key":"B33","doi-asserted-by":"publisher","first-page":"11483","DOI":"10.1038\/srep11483","article-title":"CAR-engineered NK Cells Targeting Wild-type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells","volume":"5","author":"Han","year":"2015","journal-title":"Sci. Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/neuonc\/noaa278","article-title":"Cell-surface Antigen Profiling of Pediatric Brain Tumors: B7-H3 Is Consistently Expressed and Can Be Targeted via Local or Systemic CAR T-Cell Delivery","volume":"23","author":"Haydar","year":"2020","journal-title":"Neuro Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1215\/S1152851705000074","article-title":"Increased Efficacy of an Interleukin-12-Secreting Herpes Simplex Virus in a Syngeneic Intracranial Murine Glioma Model","volume":"7","author":"Hellums","year":"2005","journal-title":"Neuro Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.cell.2018.09.038","article-title":"Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor","volume":"175","author":"Hu","year":"2018","journal-title":"Cell"},{"key":"B37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/aps.2017.125","article-title":"Chimeric Antigen Receptor (CAR)-transduced Natural Killer Cells in Tumor Immunotherapy","volume":"39","author":"Hu","year":"2018","journal-title":"Acta Pharmacol. Sin"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/nm.4204","article-title":"Recurrent MET Fusion Genes Represent a Drug Target in Pediatric Glioblastoma","volume":"22","year":"2016","journal-title":"Nat. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1158\/0008-5472.CAN-17-0468","article-title":"Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination","volume":"77","author":"Jiang","year":"2017","journal-title":"Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/neuonc\/nox116","article-title":"CD70, a Novel Target of CAR T-Cell Therapy for Gliomas","volume":"20","author":"Jin","year":"2018","journal-title":"Neuro Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.1158\/0008-5472.CAN-11-3760","article-title":"MET Signaling Regulates Glioblastoma Stem Cells","volume":"72","author":"Joo","year":"2012","journal-title":"Cancer Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3390\/ijms18061295","article-title":"EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment","volume":"18","author":"Keller","year":"2017","journal-title":"Ijms"},{"key":"B43","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/01.COC.0000020922.66984.E7","article-title":"Role of Her-2\/neu Overexpression and Clinical Determinants of Early Mortality in Glioblastoma Multiforme","volume":"26","author":"Koka","year":"2003","journal-title":"Am. J. Clin. Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1093\/jnci\/djm229","article-title":"Effect of Tumor Microenvironment Modulation on the Efficacy of Oncolytic Virus Therapy","volume":"99","author":"Kurozumi","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"B45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/cgt.2008.46","article-title":"An Oncolytic Adenovirus Expressing Granulocyte Macrophage colony-stimulating Factor Shows Improved Specificity and Efficacy for Treating Human Solid Tumors","volume":"16","author":"Lei","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.3390\/ijms20215347","article-title":"PD-L1\/PD-1 Axis in Glioblastoma Multiforme","volume":"20","author":"Litak","year":"2019","journal-title":"Ijms"},{"key":"B47","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.molcel.2015.09.002","article-title":"EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling","volume":"60","author":"Liu","year":"2015","journal-title":"Mol. Cel"},{"key":"B48","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12935-019-1085-6","article-title":"CTLA-4 Correlates with Immune and Clinical Characteristics of Glioma","volume":"20","author":"Liu","year":"2020","journal-title":"Cancer Cel Int"},{"key":"B49","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.1158\/0008-5472.CAN-03-3504","article-title":"HER-2, Gp100, and MAGE-1 Are Expressed in Human Glioblastoma and Recognized by Cytotoxic T Cells","volume":"64","author":"Liu","year":"2004","journal-title":"Cancer Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"11803","DOI":"10.2147\/CMAR.S274605","article-title":"Antitumor Efficacy of Oncolytic Herpes Virus Type 1 Armed with GM-CSF in Murine Uveal Melanoma Xenografts","volume":"12","author":"Liu","year":"","journal-title":"Cmar"},{"key":"B51","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.canlet.2020.09.013","article-title":"Antitumor Efficacy of Oncolytic HSV-1 Expressing Cytosine Deaminase Is Synergistically Enhanced by DPD Down-Regulation and EMT Inhibition in Uveal Melanoma Xenograft","volume":"495","author":"Liu","year":"","journal-title":"Cancer Lett."},{"key":"B52","doi-asserted-by":"publisher","first-page":"108285","DOI":"10.1016\/j.exer.2020.108285","article-title":"Macrophage Polarization Contributes to the Efficacy of an Oncolytic HSV-1 Targeting Human Uveal Melanoma in a Murine Xenograft Model","volume":"202","author":"Liu","year":"2021","journal-title":"Exp. Eye Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1038\/mt.2010.183","article-title":"Efficacy and Safety\/toxicity Study of Recombinant Vaccinia Virus JX-594 in Two Immunocompetent Animal Models of Glioma","volume":"18","author":"Lun","year":"2010","journal-title":"Mol. Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"9982","DOI":"10.1158\/0008-5472.Can-05-1201","article-title":"Myxoma Virus Is a Novel Oncolytic Virus with Significant Antitumor Activity against Experimental Human Gliomas","volume":"65","author":"Lun","year":"2005","journal-title":"Cancer Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/cancers11020186","article-title":"Virus-Based Immunotherapy of Glioblastoma","volume":"11","author":"Martikainen","year":"2019","journal-title":"Cancers"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1038\/s41467-019-10043-0","article-title":"The Oncolytic Virus Delta-24-RGD Elicits an Antitumor Effect in Pediatric Glioma and DIPG Mouse Models","volume":"10","author":"Mart\u00ednez-V\u00e9lez","year":"2019","journal-title":"Nat. Commun."},{"key":"B57","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ebiom.2019.01.067","article-title":"DNA Damage Repair Alterations Modulate M2 Polarization of Microglia to Remodel the Tumor Microenvironment via the P53-Mediated MDK Expression in Glioma","volume":"41","author":"Meng","year":"2019","journal-title":"EBioMedicine"},{"key":"B58","doi-asserted-by":"publisher","first-page":"6190","DOI":"10.1158\/1078-0432.CCR-17-0681","article-title":"Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte-Associated Protein Blockade","volume":"23","author":"Moesta","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/neuonc\/noy008","article-title":"SYK Inhibition Blocks Proliferation and Migration of Glioma Cells and Modifies the Tumor Microenvironment","volume":"20","author":"Moncayo","year":"2018","journal-title":"Neuro Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/neuonc\/nov172","article-title":"PD-L1 Expression and Prognostic Impact in Glioblastoma","volume":"18","author":"Nduom","year":"2016","journal-title":"Neuro Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ebiom.2019.08.030","article-title":"B7-H3-redirected Chimeric Antigen Receptor T Cells Target Glioblastoma and Neurospheres","volume":"47","author":"Nehama","year":"2019","journal-title":"EBioMedicine"},{"key":"B62","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A Single Dose of Peripherally Infused EGFRvIII-Directed CAR T Cells Mediates Antigen Loss and Induces Adaptive Resistance in Patients with Recurrent Glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci. Transl Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1101\/gad.1972310","article-title":"PDGFRA Gene Rearrangements Are Frequent Genetic Events in PDGFRA-Amplified Glioblastomas","volume":"24","author":"Ozawa","year":"2010","journal-title":"Genes Dev."},{"key":"B64","doi-asserted-by":"publisher","first-page":"eaaz1863","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective Combination Immunotherapy Using Oncolytic Viruses to Deliver CAR Targets to Solid Tumors","volume":"12","author":"Park","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/bpa.12043","article-title":"PDGFRAAmplification Is Common in Pediatric and Adult High-Grade Astrocytomas and Identifies a Poor Prognostic Group in IDH1 Mutant Glioblastoma","volume":"23","author":"Phillips","year":"2013","journal-title":"Brain Pathol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ymthe.2018.02.001","article-title":"Adoptive Transfer of IL13R\u03b12-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma","volume":"26","author":"Pituch","year":"2018","journal-title":"Mol. Ther."},{"key":"B68","first-page":"1103","article-title":"IL-13R(alpha)2, a Decoy Receptor for IL-13 Acts as an Inhibitor of IL-4-dependent Signal Transduction in Glioblastoma Cells","volume":"62","author":"Rahaman","year":"2002","journal-title":"Cancer Res."},{"key":"B69","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ccell.2017.07.006","article-title":"Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade","volume":"32","author":"Saha","year":"2017","journal-title":"Cancer Cell"},{"key":"B70","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2217\/imt-2018-0009","article-title":"Oncolytic Herpes Simplex Virus Immunovirotherapy in Combination with Immune Checkpoint Blockade to Treat Glioblastoma","volume":"10","author":"Saha","year":"2018","journal-title":"Immunotherapy"},{"key":"B71","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41586-018-0499-y","article-title":"A Homing System Targets Therapeutic T Cells to Brain Cancer","volume":"561","author":"Samaha","year":"2018","journal-title":"Nature"},{"key":"B72","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/BF01052920","article-title":"Amplification and Differential Expression of Members of theerbB-Gene Family in Human Glioblastoma","volume":"22","author":"Schlegel","year":"1994","journal-title":"J. Neuro-oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"N42","DOI":"10.1093\/neuros\/nyx449","article-title":"Use of HER2-specific Chimeric Antigen Receptor-Modified Virus-specific T Cells as a Potential Therapeutic for Progressive HER2-Positive Glioblastoma","volume":"81","author":"Schneider","year":"2017","journal-title":"Neurosurgery"},{"key":"B74","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/mt.2014.219","article-title":"Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2\/HER2-specific Chimeric Antigen Receptor","volume":"23","author":"Sch\u00f6nfeld","year":"2015","journal-title":"Mol. Ther."},{"key":"B75","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The Diverse Functions of the PD1 Inhibitory Pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"e33844","DOI":"10.1371\/journal.pone.0033844","article-title":"miR-34a Repression in Proneural Malignant Gliomas Upregulates Expression of its Target PDGFRA and Promotes Tumorigenesis","volume":"7","author":"Silber","year":"2012","journal-title":"PloS one"},{"key":"B77","doi-asserted-by":"publisher","first-page":"104112","DOI":"10.1016\/j.cellimm.2020.104112","article-title":"Combined Antitumor Effects of Anti-EGFR Variant III CAR-T Cell Therapy and PD-1 Checkpoint Blockade on Glioblastoma in Mouse Model","volume":"352","author":"Song","year":"2020","journal-title":"Cell Immunol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/cgt.2011.81","article-title":"Expressing Human Interleukin-15 from Oncolytic Vesicular Stomatitis Virus Improves Survival in a Murine Metastatic colon Adenocarcinoma Model through the Enhancement of Anti-tumor Immunity","volume":"19","author":"Stephenson","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"B79","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.omto.2019.07.002","article-title":"B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma","volume":"14","author":"Tang","year":"2019","journal-title":"Mol. Ther. - Oncolytics"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","article-title":"Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1093\/neuonc\/nou045","article-title":"Significance of Interleukin-13 Receptor Alpha 2-targeted Glioblastoma Therapy","volume":"16","author":"Thaci","year":"2014","journal-title":"Neuro-Oncology"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","article-title":"The Clinical Efficacy of First-Generation Carcinoembryonic Antigen (CEACAM5)-specific CAR T Cells Is Limited by Poor Persistence and Transient Pre-conditioning-dependent Respiratory Toxicity","volume":"66","author":"Thistlethwaite","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"B83","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ccell.2017.06.003","article-title":"Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment","volume":"32","author":"Wang","year":"2017","journal-title":"Cancer Cell"},{"key":"B84","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13046-019-1085-3","article-title":"Challenges and Potential of PD-1\/pd-L1 Checkpoint Blockade Immunotherapy for Glioblastoma","volume":"38","author":"Wang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1111\/cas.13744","article-title":"Genetic and Clinical Characterization of B7\u2010H3 (CD276) Expression and Epigenetic Regulation in Diffuse Brain Glioma","volume":"109","author":"Wang","year":"2018","journal-title":"Cancer Sci."},{"key":"B86","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1158\/1078-0432.CCR-17-1766","article-title":"NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma","volume":"24","author":"Weiss","year":"","journal-title":"Clin. Cancer Res."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1158\/0008-5472.CAN-17-1788","article-title":"NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma","volume":"78","author":"Weiss","year":"","journal-title":"Cancer Res."},{"key":"B88","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1215\/15228517-2007-003","article-title":"Methylation of the PTEN Promoter Defines Low-Grade Gliomas and Secondary Glioblastoma","volume":"9","author":"Wiencke","year":"2007","journal-title":"Neuro Oncol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00432-018-2786-2","article-title":"Glioma Stem Cells Reconstruct Similar Immunoinflammatory Microenvironment in Different Transplant Sites and Induce Malignant Transformation of Tumor Microenvironment Cells","volume":"145","author":"Xie","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s40425-019-0642-9","article-title":"T Cells Expressing NKG2D Chimeric Antigen Receptors Efficiently Eliminate Glioblastoma and Cancer Stem Cells","volume":"7","author":"Yang","year":"2019","journal-title":"J. Immunotherapy Cancer"},{"key":"B91","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.canlet.2017.06.024","article-title":"Targeting EGFRvIII for Glioblastoma Multiforme","volume":"403","author":"Yang","year":"2017","journal-title":"Cancer Lett."},{"key":"B92","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.7150\/thno.43991","article-title":"Tandem CAR-T Cells Targeting CD70 and B7-H3 Exhibit Potent Preclinical Activity against Multiple Solid Tumors","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1172\/JCI98047","article-title":"PD-L1 in Tumor Microenvironment Mediates Resistance to Oncolytic Immunotherapy","volume":"128","author":"Zamarin","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv375","article-title":"ErbB2\/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma","volume":"108","author":"Zhang","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","article-title":"Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA + Metastatic Colorectal Cancers","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol. Ther."},{"key":"B96","doi-asserted-by":"publisher","first-page":"e1461304","DOI":"10.1080\/2162402X.2018.1461304","article-title":"Large-scale Analysis Reveals the Specific Clinical and Immune Features of B7-H3 in Glioma","volume":"7","author":"Zhang","year":"2018","journal-title":"Oncoimmunology"},{"key":"B97","doi-asserted-by":"publisher","first-page":"9085","DOI":"10.2147\/ott.s265322","article-title":"Biological Characterization and Therapeutics for Subscalp Recurrent in Intracranial Glioblastoma","volume":"13","author":"Zhang","year":"2020","journal-title":"Ott"},{"key":"B98","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41419-020-2696-5","article-title":"Advances and Potential Pitfalls of Oncolytic Viruses Expressing Immunomodulatory Transgene Therapy for Malignant Gliomas","volume":"11","author":"Zhang","year":"2020","journal-title":"Cell Death Dis."},{"key":"B99","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s13287-018-0977-z","article-title":"Current Status and Potential Challenges of Mesenchymal Stem Cell-Based Therapy for Malignant Gliomas","volume":"9","author":"Zhang","year":"2018","journal-title":"Stem Cel Res. Ther."},{"key":"B100","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13578-020-00485-1","article-title":"Efficacy of a Novel Double-Controlled Oncolytic Adenovirus Driven by the Ki67 Core Promoter and Armed with IL-15 against Glioblastoma Cells","volume":"10","author":"Zhang","year":"2020","journal-title":"Cell Biosci"},{"key":"B101","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1089\/hum.2019.352","article-title":"Efficacy of an Oncolytic Adenovirus Driven by a Chimeric Promoter and Armed with Decorin against Renal Cell Carcinoma","volume":"31","author":"Zhang","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"B102","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.bbrc.2018.10.151","article-title":"Generation of Regulable EGFRvIII Targeted Chimeric Antigen Receptor T Cells for Adoptive Cell Therapy of Glioblastoma","volume":"507","author":"Zheng","year":"2018","journal-title":"Biochem. Biophysical Res. Commun."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.2147\/OTT.S237841","article-title":"B7-H3 Regulates Glioma Growth and Cell Invasion through a JAK2\/STAT3\/Slug-dependent Signaling Pathway","volume":"13","author":"Zhong","year":"2020","journal-title":"Ott"},{"key":"B104","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1007\/s12253-019-00759-1","article-title":"EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-glioma Activity","volume":"26","author":"Zhu","year":"","journal-title":"Pathol. Oncol. Res."},{"key":"B105","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1007\/s12253-019-00759-1","article-title":"EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-glioma Activity","volume":"26","author":"Zhu","year":"","journal-title":"Pathol. Oncol. Res."},{"key":"B106","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ccr.2005.07.004","article-title":"Early Inactivation of P53 Tumor Suppressor Gene Cooperating with NF1 Loss Induces Malignant Astrocytoma","volume":"8","author":"Zhu","year":"2005","journal-title":"Cancer Cell"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.661606\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T09:02:20Z","timestamp":1625734940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.661606\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,24]]},"references-count":106,"alternative-id":["10.3389\/fphar.2021.661606"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.661606","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,24]]},"article-number":"661606"}}